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Abstract
Background: The incidence of hepatocellular cancer in complicated alcoholic and non-alcoholic fatty liver diseases
is on the rise in western countries as well in our country. Vascular adhesion protein-1 (VAP-1) levels have been
presented as new marker. In our study protocol, we assessed the value of this serum protein, as a newly postulant
biomarker for hepatocellular cancer in patients with a history of alcoholic and non-alcoholic fatty liver diseases.
Methods: Pre-operative serum samples from 55 patients with hepatocellular cancer with a history of alcoholic and
non-alcoholic fatty liver diseases and patients with cirrhosis were assessed by a quantitative sandwich ELISA using
anti-VAP-1 mAbs. This technique is used to determine the levels of soluble VAP-1 (sVAP-1) in the serum.
Results: sVAP-1 levels were evaluated in patients with hepatocellular cancer and liver cirrhosis. There was a
significant difference in mean VAP-1 levels between groups. Serum VAP-1 levels were found higher in patients with
hepatocellular cancer.
Conclusion: These findings indicate that the serum level of sVAP-1 might be a beneficial marker of disease activity
in chronic liver diseases.
Introduction
Hepatocellular carcinoma (HCC) is a major health pro-
blem worldwide, with more than 5,00,000 cases diag-
nosed annually [1]. There has been an increase in the
incidence of HCC over the last 5-8 years, however, the
survival of those who have been diagnosed as HCC has
not changed significantly in the last two decades [1,2].
Etiologies of the tumors in our HCC patients were
mainly in alcoholic and non-alcoholic fatty liver dis-
eases. Vascular adhesion protein-1 (VAP-1) has been
used for the diagnosis of HCC arising from steatohepati-
tis associated with cirrhosis as an important marker.
VAP-1 is one of the endothelial cell adhesion mole-
cules that mediate binding of lymphocytes to the
endothelium under some conditions [3,4]. It is primarily
expressed in high endothelial venules in peripheral
lymph nodes. Furthermore, the expression of VAP-1 is
induced and up-regulated by chronic inflammation in
the vessels of the tonsil, gut, skin, and synovium [5].
VAP-1 is present on sinusoidal and vascular endothelia
in the liver under both normal and inflammatory condi-
tions [6].
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glycoprotein that consists of two 90 kDa subunits con-
nected together by disulfide bonds [7]. VAP-1 has a big
extracellular domain, a single-pass trans-membrane
domain, and a short cytoplasmic line [8].
The molecule has effusive sialic acid decorations that
are descended to its tenacious function, but VAP-1 is
incapable to mediate lymphocyte adhesion to desialy-
lated vessels [7].
Recently, most of the leukocyte-endothelial cell adhe-
sion molecules, such as ICAM-1, VCAM-1, platelet
endothelial cell adhesion molecule-1, selectins (E-selec-
tin, P-selectin, L-selectin) have been demonstrated to
circulate in soluble forms [9-12]. Extracellular parts of
L- and E-selectin, VCAM-1, and ICAM-1 are enzymati-
cally ruptured from the cell surface and released into
the bloodstream [13]. This process is one of the
mechanisms by which soluble forms of adhesion
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soluble adhesion molecules and contrasting physiologic
effects. They may function as inhibitors of cell to cell
adhesion by competing with their membrane-bound
forms [14]. Alternatively, soluble molecules can trigger
responses in cells that bear their ligands [15]. Moreover,
because the levels of these adhesion molecules change
in different states, the determination of their concentra-
tions can be beneficial for the diagnosis and treatment
and monitoring of diseases [9,12,16,17].
In this study, we aimed to demonstrate that sVAP-1
levels can be elevated in patients with alcoholic and
non-alcoholic fatty liver diseases preceding hepatocellu-
lar cancer. We suggest that the increased levels of
sVAP-1 may be a clinically useful marker in liver
diseases.
Materials and methods
History and clinical properties were interrogated and
serum samples were collected after approval by Haseki
Education and Research Hospital Ethics Committee
approved this study. Informed consent was obtained
from all patients. All patients were diagnosed with HCC
as proposed by the European Association for the Study
of the liver [18]. Pre-operative 55 patients with HCC, all
of whom had cirrhosis, were selected for study. Of
these, 33 patients had alcoholic liver disease and 22
patients non-alcoholic fatty liver disease. The diagnosis
of non-alcoholic fatty liver disease cirrhosis was made in
patients who had clinical features and liver biopsies
compatible with non-alcoholic fatty disease. Females and
males consuming greater than 15 or 20 units of alcohol
per week respectively were excepted from this category,
as were any individuals with viral or autoimmune liver
diseases. The presence of steatosis and stage 4 fibrosis
defined by modified Brunt criteria was necessary for the
diagnosis [19]. Patients with positive results for either
HBsAg or HCV were excluded from this study. Blood
was transfered into serum tubes. After centrifugation at
3000 rpm for 10 min, serum was collected, aliquoted,
and kept frozen at -70 °C, sVAP-1 was studied in this
serum by ELISA.
sVAP-1 ELISA
Wells of microtiter plates (96-well, flat-bottom, white
Cliniplate EB; Labsystems) were coated with 100 μLo f
the anti-VAP-1 mAb TK8-18 at 10 μg/mL in 0.1 M
NaHCO3 buffer (pH 9.6) at 4° C overnight and then at
37° C for 1 h. The wells were washed six times with
0.1% Tween 20 in PBS (Tween/PBS) and then blocked
to prevent non-specific adsorption by the addition of
200 μL of PBS containing 1% gelatin and 1% nonfat
milk powder, a blocking solution, for 45 min at room
temperature. After washing the wells six times with
Tween/PBS, 175 μL of each serum sample at 1:25 dilu-
tion in the blocking solution, it was added into the
wells, and the plates were left at room temperature for 1
h. The wells were then washed six times with Tween/
PBS and incubated with 100 μL of the biotinylated anti-
VAP-1 mAb TK8-14 or biotinylated control mAB
Hermes-3, 10 μg/mL in the blocking solution, at room
temperature for 1 h. After washing six times with
Tween/PBS, 100 μL of streptavidin-horse-radish peroxi-
dase was added into the wells, and the plates were
allowed to incubate at room temperature again for 1 h.
Finally, plates were washed six times with Tween/PBS
and generated after combining with chemiluminescence
ELISA reagent (Boehringer Mannheim, Germany)
according to the manufacturer’s instructions. The inten-
sities of the chemiluminescence reactions in the wells
were always measured after a 3-min incubation time.
Each sample was measured in triplicate with both
the anti-VAP-1 mAb and the negative control mAb.
T h es p e c i f i cV A P - 1v a l u ew a scalculated by subtracting
the mean background value of the negative control from
the mean value of VAP-1 [20].
Statistical analysis
Data obtained by Shapiro Wilk normality test were done
with leaf and steam. Correlations were performed using
Spearman’s correlation test.
Results and discussion
Serum VAP-1 levels were determined in 55 patients
with HCC arising from both alcoholic cirrhosis and
non-alcoholic fatty liver disease. A control group con-
sists of 46 patients with alcoholic cirrhosis and non-
alcoholic fatty liver disease. The clinical characteristics
of the patients in these groups are shown in Table 1.
Mean VAP-1 levels were significantly different
between patients with HCC and liver cirrhosis, as
shown in Table 2 (p < 0.01).
There were no age or gender differences between cir-
rhosis and HCC patient groups. However, serum VAP-1
Table 1 Clinical characteristics of the patients with
cirrhosis and cirrhosis plus HCC
Cirrhosis HCC
Number 46 55
Age (years) 56.4 ± 8.6 58.9 ± 7.3
Male:Female 27:19 39:16
Alcoholic:non-alcoholic 30:16 30:25
Portal vein invasion NA 11
Single nodule NA 14
Two nodules NA 10
≥ 3 nodules NA 18
NA: Not applicable.
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(respectively; 98.4 ± 12.6, 105.0 ± 10.2) (p < 0.01).
There was a difference between levels of VAP-1 in
patients with HCC- associated alcoholic liver diseases
and with HCC-associated non-alcoholic liver diseases.
We found VAP-1 on a significantly higher level in
patients with HCC-associated alcoholic liver diseases
(p < 0.01). But, there were correlation between levels of
sVAP-1 in patients with HCC-associated alcoholic liver
diseases and in patients with HCC-associated non-alco-
holic liver diseases (p < 0.01, r = 0.61).
We found a correlation between the patients with
total HCC and the patients with HCC-associated alco-
holic liver diseases and HCC-associated non-alcoholic
liver diseases (p < 0.01, r = 0.51). Also, there were corre-
lation between healthy individuals and patients with
total HCC (r = 0.59, p < 0.01).
The elevation incidence of HCC [2], is usually related
to the the fact that the generality of these tumors are
diagnosed at stage III or stage IV, when curative treat-
ments are not possible [21].
Our results represent a tremendous amount of VAP-1.
In our study, serum VAP-1 has a moderate significance
as a biomarker of HCC in alcoholic cirrhosis and non-
alcoholic fatty liver disease patients, with a sensitivity of
98% (10 ng/mL) in combination with a specificity of
100%. The threshold level of VAP-1 for diagnosis of
HCC is a 100 ng/mL [20]. The concentrations of VAP-1
measured by ELISA in healthy person were found to be
between 21 and 89 ng/mL [20]. No age or sex correla-
tions were observed.
Significantly increased levels of VAP-1 were found in
patients with HCC. Patients with HCC had the most
marked elevations in systemic circulation. The increased
serum levels in these patients were quite enough to sug-
gest that the concentrations of VAP-1 could cause bio-
logic effects. This finding is involved, because these
patients are diagnosed and treatment as HCC.
In our study, we found higher levels of VAP-1 in
patients with HCC-associated alcoholic liver diseases.
This protein is significantly increased in the serum of
HCC patients, but it is not elevated in neither HCV
associated HCC patients nor patients with steatohepati-
tis related HCC, however patients diagnosed as steato-
hepatitis cirrhosis alone have high concentrations. The
mechanism of this differentiation is unclear. It is
possible that this newly protein as a candidate biomar-
ker, mixed to other endothelial adhesion molecules, may
yet improve their mechanisms.
Toiyama and collegaous [22] assessed the sVAP-1
levels in patients with colorectal cancer and they found
a decrease in the sVAP-1 levels.
In conclusion, we have shown that sVAP-1 is present
in the serum of patients with HCC. Moreover, the level
of VAP-1 is increased in liver diseases in a more dis-
ease-specific manner than the levels of other known
present adhesion molecules [16]. VAP-1 may dominant
its biologic function by the endothelial cell adhesion cas-
cade. We suggested that this protein may be a signifi-
cant marker for HCC in patient with alcoholic and non-
alcoholic fatty liver diseases.
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